圣犹大团队识别出预示神经母细胞瘤不良预后的细胞类型及基因表达签名
Scientists identify the neuroblastoma cells that signal poor outcomes
圣犹大儿童研究医院团队在 Cancer Cell 发表研究,识别出与神经母细胞瘤不良预后相关的恶性间充质细胞并定义基因表达签名。团队分析 50 名患者的 54 个肿瘤,结合单细胞 RNA 测序与空间组学构建数据集,并经患者来源异种移植模型分离出该签名;在独立数据中,新签名预测预后优于旧方法。相关患者来源模型与细胞系可通过 CSTN 申请获取。
Neuroblastoma is the most common solid tumor found outside the brain in children, yet why some children respond well to treatment while others do not has remained poorly understood. St. Jude Children's Research Hospital scientists and their collaborators built one of the most comprehensive datasets of neuroblastoma cells to date, using it to define the tumor's cell types and identify a gene signature marking a malignant cell population tied to poor prognosis.
The team also created patient-derived models that capture this population, which older laboratory cell lines had missed. The findings, published today in Cancer Cell, give researchers a new framework and a set of tools to study high-risk neuroblastoma.
Neuroblastoma cells are divided into two cell states: adrenergic cells (which are associated with low-risk disease) and mesenchymal cells (which are associated with high-risk disease, treatment resistance and poor outcomes). However, directly identifying cancer-related mesenchymal cells in patient tumors has been challenging because the body also contains healthy mesenchymal cells, which can be mistaken for their malignant counterparts, complicating efforts to study them.
To find a better way to identify these treatment-resistant cancer cells, the researchers looked at 54 tumors from 50 patients. The scientists constructed one of the most comprehensive datasets of neuroblastoma cells to date, incorporating multiple cutting-edge technologies, including single-cell RNA sequencing and spatial omics.
By leveraging patient-derived xenografts, which are patient tumor cells grown within mice, the team isolated a clear gene expression profile connected to malignant mesenchymal cells. The healthy mesenchymal cells from the patient's tumor do not grow in xenografts. The xenografted tumor cells, which were generated as part of the St. Jude Childhood Solid Tumor Network (CSTN), were crucial both in proving that these cells exist and in defining their molecular and cellular features.
"With this new gene expression signature for mesenchymal cells in neuroblastoma, we can dig into why outcomes are so varied between different children with this cancer," said co-corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology.
To verify that this newfound signature was more effective than previous methods at identifying cancer-related mesenchymal cells in patient tumors, the researchers tested it using an independent database of patient tumor RNA sequencing data. The new signal improved predictions for outcomes significantly, while a preexisting signature from decades-old cell lines did not.
Validating a new gene expression signature in neuroblastoma
To assess the signature, the researchers created organoids (three-dimensional growths of cancer cells formed in the lab) and cell lines, in addition to their xenografts. The scientists used multiple approaches across these systems, including spatial transcriptomics, spatial proteomics, electron microscopy and chromatin profiling. The gene expression signature differentiated between the two neuroblastoma cell types in all cases. The scientists also found the two cell types had distinct cellular shapes, internal spatial organization and behaviors.
"I'm just endlessly fascinated by the signature itself, because regardless of the test, it's been very robust," said first author Anand Patel, M.D., Ph.D., of the St. Jude Department of Oncology. "These markers are going to be powerful tools to understand neuroblastoma better."
With the marker identified and validated, the group created additional in vitro models and new cell lines from xenografts derived from patient samples that had varying proportions of mesenchymal to adrenergic cells. Those models are available upon request through the CSTN, giving researchers a resource that could reinvigorate investigations into high-risk disease. Those tools may help scientists better understand tumor cell states, identify vulnerabilities and evaluate potential treatment strategies.
"Our new models are a launching point for neuroblastoma research," said co-corresponding author Elizabeth Stewart, M.D., of the St. Jude Department of Oncology. "Using this dataset as our foundation, the field is poised to explore the biology of this pediatric cancer more deeply and ultimately move us toward improving our patients' outcomes."
Publication details
Anand G. Patel et al, Spatial omics resolves adrenergic and mesenchymal cell states in neuroblastoma, Cancer Cell (2026). DOI: 10.1016/j.ccell.2026.09.008
Journal information: Cancer Cell
Key medical concepts
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Scientists identify the neuroblastoma cells that signal poor outcomes (2026, October 8) retrieved 8 October 2026 from https://medicalxpress.com/news/2026-10-scientists-neuroblastoma-cells-poor-outcomes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com